latest news

Promethera Biosciences Completes €39.7 Million ($44.4 Million) Series D Financing

Proceeds will support ongoing clinical evaluation of HepaStem® in ACLF and launch of a clinical trial in late stage NASH set to commence in H1 2019 in Europe with significant further expansion into the US and Asia. Discover the press release here.